Clinical | CLL Society

Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right?

When CNN has a headline that Chemo-free drug combo shows 'dramatic' improvement against common leukemia in adults and reports on... Details

Acalabrutinib Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and will stop early

This trial in previously treated CLL patients showed a clinically significant progression free survival when compared to a combination regimen... Details

Get Ready for Flu Season

When it comes to contagious diseases like the flu, CLL patients are among the most vulnerable to infection and serious... Details

Blood Cancer Awareness Month

Blood Cancer Awareness Month takes place every September. The CLL Society joins 100s of other nonprofits and charities in promoting... Details

Phase III Data Showed That Venclexta Plus Rituxan Extends Progression Free Survival in Relapsed Refractory CLL Compared to Bendamustine Plus Rituxan

September 18, 2017 -- AbbVie and Genentech, a member of the Roche Group, announced that the Phase III MURANO study... Details

News on Ublituximab

February 21, 2017 - Clinical data from the Phase 1/2 Trial of TG-1101 (ublituximab) monotherapy has been published in the... Details

Pivotal Phase II Study of Venetoclax Met Primary Endpoint in a Hard-to-Treat Type of CLL

Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers,... Details

EHA 2015: Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory CLL (chronic lymphocytic leukemia)

At the 20th Congress of the European Hematology Association (EHA), June 11-15, 2015 in Vienna, Austria, an oral presentation reported... Details

Phase III RESONATE-2 That Compared Ibrutinib To Chlorambucil In > 65 Year Old Treatment Naïve Patients Excluding Those With Deletion 17p

Take Away Points: Ibrutinib is superior to chlorambucil for frontline therapy in those treatment naïve patients >65 without deletion 17p. This could... Details

The Addition Of Ibrutinib To BR (Bendamustine-Rituximab) Improves Progression-Free Survival (PFS)

Patients in the BR arm are allowed to crossover While this press release from Pharmacyclics broadens the potential role of ibrutinib... Details